|
|
RNadjuvant |
|
Vaxjo ID |
323 |
|
Vaccine Adjuvant Name |
RNadjuvant |
|
Adjuvant VO ID |
VO_0005697
|
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
consists of a 547-nt uncapped noncoding ssRNA containing polyU repeats that is stabilized by a cationic carrier peptide. |
|
Structure |
547-nt uncapped noncoding ssRNA containing polyU repeats, stabilized by a cationic carrier peptide. |
|
Function |
This adjuvant consists of a 547-nt uncapped noncoding ssRNA containing polyU repeats that is stabilized by a cationic carrier peptide. |
|
Safety |
Implies good tolerability and a favorable safety profile due to inducing local IFN-I responses and no systemic effects upon i.m. injection. |
| References |
Ziegler et al., 2017: Ziegler A, Soldner C, Lienenklaus S, Spanier J, Trittel S, Riese P, Kramps T, Weiss S, Heidenreich R, Jasny E, Guzmán CA, Kallen KJ, Fotin-Mleczek M, Kalinke U. A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects. Journal of immunology (Baltimore, Md. : 1950). 2017; 198(4); 1595-1605. [PubMed: 28077601].
|
|
